2023
The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumors
2019
A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk
Klimov S, Miligy I, Gertych A, Jiang Y, Toss M, Rida P, Ellis I, Green A, Krishnamurti U, Rakha E, Aneja R. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research 2019, 21: 83. PMID: 31358020, PMCID: PMC6664779, DOI: 10.1186/s13058-019-1165-5.Peer-Reviewed Original ResearchConceptsDCIS patientsRecurrence riskDuctal carcinomaScreen-detected breast cancerLong-term outcome dataBreast-conserving surgeryUnmet clinical needNottingham University HospitalsPositive predictive valueAdjuvant radiationIpsilateral recurrenceAdditional therapyMethodsThe cohortHazard ratioLocal recurrenceClinicopathological markersClinicopathological variablesPrimary tumorUniversity HospitalLymphocyte regionBreast cancerOutcome dataBenign ductsPredictive valuePatientsPrognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li X, Oprea-Ilies G, Wetherilt C, Riaz A, Aleskandarany M, Green A, Ellis I, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen E, Callagy G, Walsh E, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada H, Omonisi A, Ahmed S, Rakha E, Rida P, Aneja R. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers 2019, 11: 995. PMID: 31319547, PMCID: PMC6678933, DOI: 10.3390/cancers11070995.Peer-Reviewed Original ResearchTriple-negative breast cancerAR-positive triple-negative breast cancerAndrogen receptorAR statusPrognostic roleOverall survivalBetter prognosisBreast cancerAR-positive nucleiPatients' overall survivalReliable prognostic markersNegative breast cancerPotential therapeutic targetMulti-institutional studyAR positivityTNBC patientsPoor prognosisPrognostic valuePrimary tumorPatient prognosisIndian cohortPrognostic markerUK cohortAR antibodyTNBC samples